Takashi Saito1, Daisuke Makiura2, Junichiro Inoue2, Hisayo Doi3, Kimikazu Yakushijin4, Atsuo Okamura5, Hiroshi Matsuoka4, Toru Mukohara6, Ryuichi Saura7, Yoshitada Sakai8, Rei Ono1. 1. Department of Public Health Sciences, Kobe University Graduate School of Health Sciences. 2. Division of Rehabilitation, Kobe University Hospital. 3. Division of Nursing, Kobe University Hospital. 4. Department of Medical Oncology and Hematology, Kobe University Hospital. 5. Department of Medical Oncology and Hematology, Kakogawa Central City Hospital. 6. Department of Breast and Medical Oncology, National Cancer Center Hospital East. 7. Department of Physical and Rehabilitation Medicine, Osaka Medical College. 8. Department of Rehabilitation Medicine, Kobe University Graduate School of Medicine.
Abstract
OBJECTIVE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event experienced by cancer patients. In general, CIPN is evaluated subjectively based on patient self-assessment or clinician-reported scales; evidence supporting the utility and validity of quantitative sensory tests (QST) is lacking in this patient population. The aim of this study was to objectively assess CIPN of lower extremities by QSTs, and to evaluate the concordance between QSTs and subjective assessments. METHODS: In this prospective cohort study, outpatients with cancer receiving chemotherapy were recruited at a single university hospital. We assessed CIPN at the lower extremities at baseline and three months after baseline. The QSTs were performed by applying a monofilament and a tuning fork to determine touch and vibration thresholds, respectively, at the affected site. Subjective assessments were performed based on the visual analog scale (VAS) and the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) toxicity grade. Kappa coefficients were calculated to evaluate the concordance between QSTs and subjective assessments. RESULTS: After exclusion and drop-outs during follow-up, nineteen patients were included in the analysis. The prevalence of patients with abnormal sensation was 37% based on QSTs, 32% based on the VAS, and 14% based on CTCAE grading, respectively. Kappa coefficients were 0.32 between QSTs and VAS, and 0.28 between QSTs and CTCAE. CONCLUSIONS: The concordance rates between quantitative and subjective assessments were low. CIPN should be assessed using both quantitative and subjective assessments. 2020, JAPANESE PHYSICAL THERAPY ASSOCIATION.
OBJECTIVE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event experienced by cancerpatients. In general, CIPN is evaluated subjectively based on patient self-assessment or clinician-reported scales; evidence supporting the utility and validity of quantitative sensory tests (QST) is lacking in this patient population. The aim of this study was to objectively assess CIPN of lower extremities by QSTs, and to evaluate the concordance between QSTs and subjective assessments. METHODS: In this prospective cohort study, outpatients with cancer receiving chemotherapy were recruited at a single university hospital. We assessed CIPN at the lower extremities at baseline and three months after baseline. The QSTs were performed by applying a monofilament and a tuning fork to determine touch and vibration thresholds, respectively, at the affected site. Subjective assessments were performed based on the visual analog scale (VAS) and the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) toxicity grade. Kappa coefficients were calculated to evaluate the concordance between QSTs and subjective assessments. RESULTS: After exclusion and drop-outs during follow-up, nineteen patients were included in the analysis. The prevalence of patients with abnormal sensation was 37% based on QSTs, 32% based on the VAS, and 14% based on CTCAE grading, respectively. Kappa coefficients were 0.32 between QSTs and VAS, and 0.28 between QSTs and CTCAE. CONCLUSIONS: The concordance rates between quantitative and subjective assessments were low. CIPN should be assessed using both quantitative and subjective assessments. 2020, JAPANESE PHYSICAL THERAPY ASSOCIATION.
Authors: Miroslav-Misha Backonja; David Walk; Robert R Edwards; Nalini Sehgal; Toby Moeller-Bertram; Ajay Wasan; Gordon Irving; Charles Argoff; Mark Wallace Journal: Clin J Pain Date: 2009-09 Impact factor: 3.442
Authors: Alex Molassiotis; Hui Lin Cheng; Violeta Lopez; Joseph S K Au; Alexandre Chan; Aishwarya Bandla; K T Leung; Y C Li; K H Wong; Lorna K P Suen; Choi Wan Chan; Janelle Yorke; Carole Farrell; Raghav Sundar Journal: BMC Cancer Date: 2019-02-08 Impact factor: 4.430